Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176930 · ClinicalTrials.gov registry record · NA
Stem Cell Transplant for Hematological Malignancy
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 330
- Enrollment target
NCT00176930: Clinical Trial NA study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00176930 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 330 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00176930, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Primary Outcome
Disease-Free Survival is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- RADIATION Total Body Irradiation
- BIOLOGICAL Stem Cell Transplant
- DRUG Equine ATG (ATGAM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2001-10 |
| Est. Completion | 2019-12 |
| Phase | NA |
Why NCT00176930 stopped before completion
NCT00176930 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00176930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00176930 about?
NCT00176930 is a clinical study titled "Stem Cell Transplant for Hematological Malignancy". The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
What is the current status of trial NCT00176930?
This trial is currently terminated. It is a NA study. The enrollment target is 330 participants. The study started on 2001-10. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00176930?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Total Body Irradiation (RADIATION), Stem Cell Transplant (BIOLOGICAL), Equine ATG (ATGAM) (DRUG).
Who is sponsoring clinical trial NCT00176930?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00176930's enrollment target sits among peer trials
330 307th of 2000 higher than 1,693 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia